IART supply chain intelligence for Integra LifeSciences Holdings Corporation: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Integra LifeSciences Holdings Corporation (IART) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| MDT | Medtronic plc | 92% | The Company made a cash payment of $10.0 million upon the closing of the acquisition and will make additional cash payments of $15.0 million upon the first anniversary of the acquisition and $20.0 mi… |
| MDT | Medtronic plc | 92% | Reciprocal relationship from MDT graph: Reciprocal relationship from IART graph: The Company made a cash payment of $10.0 million upon the closing of the acquisition and will make additional cash pay… |
| DERMA-SCIENCES-INC | DERMA-SCIENCES-INC | 90% | The Company assumed contingent consideration incurred by Derma Sciences, Inc. related to its acquisitions of BioD, LLC and the intellectual property related to Medihoney® products. |
| BNS | The Bank of Nova Scotia | 85% | Reciprocal relationship from BNS graph: Reciprocal relationship from IART graph: The Bank of Nova Scotia, as Committed Lender and Group Agent |
| SURGICAL-INNOVATIONS-ASSOCIATES-INC | SURGICAL-INNOVATIONS-ASSOCIATES-INC | 85% | As part of the acquisition of Surgical Innovations Associates, Inc. (“SIA”), the Company is required to pay to the former shareholders of SIA up to $ 90.0 million for two separate payments, which are dep |
| MDXG | MiMedx Group, Inc. | 72% | rganization, our innovative technologies, and our procurement and manufacturing operations to maintain our competitive position. Our competitors for TT include Smith & Nephew plc, Organogenesis Holdi… |
| MDXG | MiMedx Group, Inc. | 72% | Reciprocal relationship from MDXG graph: ls increase their purchases of our products during the fourth quarter to coincide with the end of their budget cycles in the United States. Satisfaction of pa… |
| ORGO | Organogenesis Holdings Inc. | 72% | rganization, our innovative technologies, and our procurement and manufacturing operations to maintain our competitive position. Our competitors for TT include Smith & Nephew plc, Organogenesis Holdi… |
| ORGO | Organogenesis Holdings Inc. | 72% | Reciprocal relationship from ORGO graph: Reciprocal relationship from IART graph: rganization, our innovative technologies, and our procurement and manufacturing operations to maintain our competitiv… |
| SMTI | Sanara MedTech Inc. | 72% | Reciprocal relationship from SMTI graph: ting room etiquette and credentialing requirements. After completing their internal training, new hire field sales representatives participate in field traini… |
| SNN | Smith & Nephew plc | 72% | Reciprocal relationship from SNN graph: idends and a share buyback of $500 million; – In addition, the Orthopaedics business has returned to growth; there has been improved inventory management; and … |
| SNNUF | Smith & Nephew plc | 72% | Reciprocal relationship from SNNUF graph: Reciprocal relationship from IART graph: Reciprocal relationship from SNNUF graph: Reciprocal relationship from IART graph: rganization, our innovative techn… |
| SNNUF | Smith & Nephew plc | 72% | rganization, our innovative technologies, and our procurement and manufacturing operations to maintain our competitive position. Our competitors for TT include Smith & Nephew plc, Organogenesis Holdi… |
| STE | STERIS plc | 72% | Reciprocal relationship from STE graph: Reciprocal relationship from IART graph: usiness, including the U.S. These initiatives put increased emphasis on the delivery of more cost-effective medical de… |
| STE | STERIS plc | 72% | usiness, including the U.S. These initiatives put increased emphasis on the delivery of more cost-effective medical devices and therapies. Government programs, including Medicare and Medicaid, privat… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| USGOV-DEPARTMENT-OF-DEFENSE | USGOV-DEPARTMENT-OF-DEFENSE | 95% | USAspending awards from Department of Defense: $85,694 across 2 awards. N0018924FZ272 IP2P BRAIN PROBE KITS; N0018925FZ586 IP2P BRAIN PROBE KITS | Qwen corrected direction: Explicit government contra… |
| USGOV-DEPARTMENT-OF-HEALTH-AND-HUMAN-SERVICES | USGOV-DEPARTMENT-OF-HEALTH-AND-HUMAN-SERVICES | 95% | USAspending awards from Department of Health and Human Services: $88,210 across 1 awards. 75N90025P00591 25-007631 INTEGRA LIFESCIENCES CORPORATION CORDLESS HEADLIGHT SYSTEM AND BATTERIES | Qwen corr… |
| USGOV-DEPARTMENT-OF-VETERANS-AFFAIRS | USGOV-DEPARTMENT-OF-VETERANS-AFFAIRS | 95% | USAspending awards from Department of Veterans Affairs: $651,740 across 7 awards. 36C24625P1066 INTEGRA ULTRASONIC SURGICAL ASPIRATOR SYSTEM; 36C26325P0886 ENT SURGICAL SHAVER; 36C25023P0645 HIGHLY S… |
| MDT | Medtronic plc | 72% | Reciprocal relationship from MDT graph: Reciprocal relationship from IART graph: Durepair”), a non-synthetic dura substitute for repair of the dura mater during neurosurgical procedures, from Medtron… |
| MDT | Medtronic plc | 72% | Durepair”), a non-synthetic dura substitute for repair of the dura mater during neurosurgical procedures, from Medtronic plc for total consideration of $ 45.0 million. The Company made cash payments … |
| MDXG | MiMedx Group, Inc. | 72% | Reciprocal relationship from MDXG graph: ls increase their purchases of our products during the fourth quarter to coincide with the end of their budget cycles in the United States. Satisfaction of pa… |
| MDXG | MiMedx Group, Inc. | 72% | rganization, our innovative technologies, and our procurement and manufacturing operations to maintain our competitive position. Our competitors for TT include Smith & Nephew plc, Organogenesis Holdi… |
| ORGO | Organogenesis Holdings Inc. | 72% | rganization, our innovative technologies, and our procurement and manufacturing operations to maintain our competitive position. Our competitors for TT include Smith & Nephew plc, Organogenesis Holdi… |
| ORGO | Organogenesis Holdings Inc. | 72% | Reciprocal relationship from ORGO graph: Reciprocal relationship from IART graph: rganization, our innovative technologies, and our procurement and manufacturing operations to maintain our competitiv… |
| SMTI | Sanara MedTech Inc. | 72% | Reciprocal relationship from SMTI graph: Reciprocal relationship from IART graph: Reciprocal relationship from SMTI graph: Reciprocal relationship from IART graph: Reciprocal relationship from SMTI g… |
| SNNUF | Smith & Nephew plc | 72% | rganization, our innovative technologies, and our procurement and manufacturing operations to maintain our competitive position. Our competitors for TT include Smith & Nephew plc, Organogenesis Holdi… |
| SNNUF | Smith & Nephew plc | 72% | Reciprocal relationship from SNNUF graph: Reciprocal relationship from IART graph: rganization, our innovative technologies, and our procurement and manufacturing operations to maintain our competiti… |
| STE | STERIS plc | 72% | Reciprocal relationship from STE graph: Reciprocal relationship from IART graph: usiness, including the U.S. These initiatives put increased emphasis on the delivery of more cost-effective medical de… |
| STE | STERIS plc | 72% | usiness, including the U.S. These initiatives put increased emphasis on the delivery of more cost-effective medical devices and therapies. Government programs, including Medicare and Medicaid, privat… |
| ARKIS-BIOSCIENCES-INC | ARKIS-BIOSCIENCES-INC | 62% | — $ 13,400 Accrued expenses and other current liabilities Long-Term 7,977 2,557 300 55,300 Other liabilities Total $ 15,755 $ 2,557 $ 300 $ 68,700 F-50 INTEGRA LIFESCIENCES HOLDINGS CORPORATION NOTES… |
| BIOD-LLC | BIOD-LLC | 62% | ts: Research and development (2) Location in financial statements: Selling, general and administrative Arkis BioSciences Inc. As part of the acquisition of Arkis BioSciences Inc. (“Arkis”), the Compa… |
| DERMA-SCIENCES-INC | DERMA-SCIENCES-INC | 62% | — $ 13,400 Accrued expenses and other current liabilities Long-Term 7,977 2,557 300 55,300 Other liabilities Total $ 15,755 $ 2,557 $ 300 $ 68,700 F-50 INTEGRA LIFESCIENCES HOLDINGS CORPORATION NOTES… |
| GENTELL-LLC | GENTELL-LLC | 62% | Acquisition On December 6, 2022, the Company completed its acquisition of Surgical Innovation Associates, Inc. (“SIA”) for an acquisition purchase price of $ 51.5 million (the “SIA Acquisition”) plus… |
| SURGICAL-INNOVATION-ASSOCIATES-INC | SURGICAL-INNOVATION-ASSOCIATES-INC | 62% | easures. Governmental health systems have revised and continue to consider revisions of healthcare budgets, which could result in stricter standards for implementing certain medical procedures, incre… |
| SURGICAL-INNOVATIONS-ASSOCIATES-INC | SURGICAL-INNOVATIONS-ASSOCIATES-INC | 62% | — $ 13,400 Accrued expenses and other current liabilities Long-Term 7,977 2,557 300 55,300 Other liabilities Total $ 15,755 $ 2,557 $ 300 $ 68,700 F-50 INTEGRA LIFESCIENCES HOLDINGS CORPORATION NOTES… |
| TISSUE-TECHNOLOGIES | TISSUE-TECHNOLOGIES | 62% | al (“CSS”) and Tissue Technologies (“TT”). The CSS segment, which represents approximately two-thirds of our total revenue, consists of market-leading technologies and instrumentation used for a wide… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| IART-DEBT | Debt stack $707.2M | 90% | Market cache reports total debt of $707.2M. |
| IART-DEBT-10158 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2022-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| IART-OWNER-MORGAN-STANLEY | MORGAN STANLEY | 90% | 13F overlay lists MORGAN STANLEY as top holder; 204 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| MDXG | MiMedx Group, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| JNJ | Johnson & Johnson | 100.00 | 2 | |
| ISRG | Intuitive Surgical, Inc. | 100.00 | 2 | |
| MDWD | MediWound Ltd. | 100.00 | 2 | |
| SMTI | Sanara MedTech Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| NDRA | ENDRA Life Sciences Inc. | 100.00 | 2 | |
| IHG | InterContinental Hotels Group PLC | 100.00 | 2 | |
| GWW | W.W. Grainger, Inc. | 100.00 | 2 | |
| MDT | Medtronic plc | 100.00 | 1 | ['customer', 'supplier'] |
| BNS | The Bank of Nova Scotia | 100.00 | 1 | ['supplier'] |
| SSII | SS Innovations International, Inc. | 100.00 | 2 | |
| ORGO | Organogenesis Holdings Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| SNN | Smith & Nephew plc | 100.00 | 1 | ['supplier'] |
| PYPD | PolyPid Ltd. | 100.00 | 2 | |
| SNNUF | Smith & Nephew plc | 100.00 | 1 | ['customer', 'supplier'] |
| CUPR | Cuprina Holdings (Cayman) Limited | 100.00 | 2 | |
| AURX | Nuo Therapeutics, Inc. | 100.00 | 2 | |
| EW | Edwards Lifesciences Corporation | 100.00 | 2 | |
| DEO | Diageo plc | 100.00 | 2 | |
| NPCE | NeuroPace, Inc. | 100.00 | 2 |